Literature DB >> 29972754

Chimeric Antigen Receptor Therapy.

Carl H June1, Michel Sadelain1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29972754     DOI： 10.1056/NEJMra1706169

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  484 in total

1.  Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.

Authors:  Renier Myburgh; Jonathan D Kiefer; Norman F Russkamp; Chiara F Magnani; Nicolás Nuñez; Alexander Simonis; Surema Pfister; C Matthias Wilk; Donal McHugh; Juliane Friemel; Antonia M Müller; Burkhard Becher; Christian Münz; Maries van den Broek; Dario Neri; Markus G Manz
Journal:  Leukemia       Date:  2020-05-01       Impact factor: 11.528

Review 2.  Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.

Authors:  Rajshekhar Chakraborty; Surbhi Sidana; Gunjan L Shah; Michael Scordo; Betty K Hamilton; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-28       Impact factor: 5.742

3.  Functional TCR T cell screening using single-cell droplet microfluidics.

Authors:  Aude I Segaliny; Guideng Li; Lingshun Kong; Ci Ren; Xiaoming Chen; Jessica K Wang; David Baltimore; Guikai Wu; Weian Zhao
Journal:  Lab Chip       Date:  2018-12-04       Impact factor: 6.799

Review 4.  Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.

Authors:  Wingchi Leung; Helen E Heslop
Journal:  Cancer Immunol Res       Date:  2019-04       Impact factor: 11.151

5.  Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.

Authors:  Andrew H Ko; Alexander C Jordan; Evan Tooker; Simon F Lacey; Renee B Chang; Yan Li; Alan P Venook; Margaret Tempero; Lloyd Damon; Lawrence Fong; Mark H O'Hara; Bruce L Levine; J Joseph Melenhorst; Gabriela Plesa; Carl H June; Gregory L Beatty
Journal:  Mol Ther       Date:  2020-07-21       Impact factor: 11.454

6.  Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

Authors:  Dyantha I van der Lee; Rogier M Reijmers; Maria W Honders; Renate S Hagedoorn; Rob Cm de Jong; Michel Gd Kester; Dirk M van der Steen; Arnoud H de Ru; Christiaan Kweekel; Helena M Bijen; Inge Jedema; Hendrik Veelken; Peter A van Veelen; Mirjam Hm Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

7.  Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?

Authors:  Timothy E Krueger; Daniel L J Thorek; Alan K Meeker; John T Isaacs; W Nathaniel Brennen
Journal:  Prostate       Date:  2018-11-28       Impact factor: 4.104

8.  Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors.

Authors:  Annika M Frank; Angela H Braun; Lea Scheib; Shiwani Agarwal; Irene C Schneider; Floriane Fusil; Séverine Perian; Ugur Sahin; Frederic B Thalheimer; Els Verhoeyen; Christian J Buchholz
Journal:  Blood Adv       Date:  2020-11-24

9.  Multifocal Necrotizing Leukoencephalopathy With Preferential Microglia Toxicity in a Patient Treated With Chimeric Antigen Receptor T-Cells and Review of the Literature.

Authors:  Daniel F Marker; Julia K Kofler; Joseph A Mettenburg; Mounzer E Agha; Clayton A Wiley
Journal:  J Neuropathol Exp Neurol       Date:  2020-10-01       Impact factor: 3.685

Review 10.  Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy.

Authors:  Jacob S Appelbaum; Filippo Milano
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.